HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
| dc.contributor.author | Zhang, Haojian | |
| dc.contributor.author | Li, Huawei | |
| dc.contributor.author | Xi, Hualin S. | |
| dc.contributor.author | Li, Shaoguang | |
| dc.date | 2022-08-11T08:08:54.000 | |
| dc.date.accessioned | 2022-08-23T16:11:49Z | |
| dc.date.available | 2022-08-23T16:11:49Z | |
| dc.date.issued | 2012-03-15 | |
| dc.date.submitted | 2012-08-29 | |
| dc.identifier.citation | Blood. 2012 Mar 15;119(11):2595-607. Epub 2012 Jan 24. doi: 10.1182/blood-2011-10-387381 | |
| dc.identifier.issn | 1528-0020 | |
| dc.identifier.doi | 10.1182/blood-2011-10-387381 | |
| dc.identifier.pmid | 22275380 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/33257 | |
| dc.description.abstract | Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML. | |
| dc.language.iso | en_US | |
| dc.publisher | American Society of Hematology | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22275380&dopt=Abstract">Link to article in PubMed</a></p> | |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311277/ | |
| dc.subject | Animals | |
| dc.subject | Anoxia | |
| dc.subject | Apoptosis | |
| dc.subject | Biological Markers | |
| dc.subject | Blotting, Western | |
| dc.subject | Bone Marrow Transplantation | |
| dc.subject | Cell Cycle | |
| dc.subject | Cell Proliferation | |
| dc.subject | Cyclin-Dependent Kinase Inhibitor p16 | |
| dc.subject | Flow Cytometry | |
| dc.subject | Gene Expression Profiling | |
| dc.subject | Hypoxia-Inducible Factor 1, alpha Subunit | |
| dc.subject | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| dc.subject | Mice | |
| dc.subject | Mice, Inbred C57BL | |
| dc.subject | Mice, Knockout | |
| dc.subject | Neoplastic Stem Cells | |
| dc.subject | Oligonucleotide Array Sequence Analysis | |
| dc.subject | RNA, Messenger | |
| dc.subject | Real-Time Polymerase Chain Reaction | |
| dc.subject | Reverse Transcriptase Polymerase Chain Reaction | |
| dc.subject | Survival Rate | |
| dc.subject | UMCCTS funding | |
| dc.subject | Cancer Biology | |
| dc.subject | Hematology | |
| dc.title | HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Blood | |
| dc.source.volume | 119 | |
| dc.source.issue | 11 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/gsbs_sp/1790 | |
| dc.identifier.contextkey | 3273988 | |
| html.description.abstract | <p>Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML.</p> | |
| dc.identifier.submissionpath | gsbs_sp/1790 | |
| dc.contributor.department | Department of Biochemistry and Molecular Pharmacology | |
| dc.contributor.department | Department of Medicine, Division of Hematology/Oncology | |
| dc.source.pages | 2595-607 | |
| dc.contributor.student | Haojian Zhang |